Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma by Cong-Jun Wang et al.
Wang et al. Molecular Cancer 2012, 11:31
http://www.molecular-cancer.com/content/11/1/31RESEARCH Open AccessInterferon-α enhances antitumor activities of
oncolytic adenovirus-mediated IL-24 expression in
hepatocellular carcinoma
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Xin-Bo Xue4, Jia Fan3* and Hui Zhang1*Abstract
Background: Hepatocellular carcinoma (HCC) has a dismal 5-year-survival rate of 10%, so novel strategies are
warranted. IL-24 mediates anti-tumor activity reducing STAT3 expression, which suggests that interferon (IFN) alpha
may augment tumor cell lysis and reduce angiogenesis. We investigated the antitumor activity of treatment with
IFN-α, with the oncolytic adenovirus SG600-IL-24, or the combination of both in HCC in vitro and in vivo.
Results: RT-PCR, ELISA assay and Western-blot confirmed that the exogenous IL-24 gene was highly expressed in
HCC cells infected with SG600-IL-24. Treatment with combined IFN-α and SG600-IL-24 suppressed growth and
promoted apoptosis of the HepG2, MHCC97L, and HCCLM3 cell lines compared with the normal cell line L02. The
combined therapy increased STAT1 and SOCS1 and apoptosis, but decreased the expression of the metastatic and
angiogenic proteins MMP-2, XIAP, OPN, and VEGF, which are regulated by STAT3 in HCC cells in vitro. To assess the
effects in vivo, the HCC cell line HCCLM3 was transplanted subcutaneously into the right flanks of nude mice. Mice
in the IFN-α group, the SG600-IL-24 group, or the combined therapy group had significantly suppressed growth of
the HCC xenografted tumors compared to the PBS control group of mice. Among the mice treated with the
combination of IFN-α and SG600-IL-24, three of those eight mice had long-term survival and no evidence of a
tumor. These mice also had decreased expression of the metastatic and angiogenic proteins MMP-2, XIAP, OPN, and
VEGF.
Conclusions: The present study demonstrated for the first time the potential antitumor activity of IFN-α combined
with the oncolytic adenovirus SG600-IL-24 in HCC both in vitro and in vivo, and suggests its further development as
a potential candidate for HCC cancer gene therapy.
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Hepatocellular carcinoma (HCC) is strongly associated
with chronic infection with hepatitis B virus (HBV), liver
cirrhosis, hepatitis C virus infection, aflatoxin exposure,
and excessive alcohol consumption [1]. HCC is one of
the most common lethal malignancies in the world, and
HCC patients have a 1-year survival rate of less than
50% and a 5-year survival rate of 10% [1], despite surgery* Correspondence: jiafan99@yahoo.com; wcj902@163.com
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reproduction in any medium, provided the orand chemotherapy [2]. New modalities or combination
therapies that increase anti-tumor immune responses
and tumor cell lysis are warranted.
The melanoma differentiation associated gene-7
(MDA-7), now known as Interleukin-24 (IL-24), can in-
hibit the growth and induce the apoptosis of melanoma,
along with ovarian [3], lung [4,5], pancreas [6], prostate
[7], and colon cancers [8-12]. IL-24 was hailed as a novel
and interesting development in experimental tumor
therapy in the early 21st century [13]. We have shown
that IL-24 can selectively kill several HCC lines in vitro
[14]. IL-24 mediates its inhibition of metastases and
angiogenesis in HCC by suppressing expression of matrix
metalloproteinase 2 (MMP-2), vascular endothelial growthtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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To augment efficacy of IL-24, we searched for a comple-
mentary anti-tumor protein to deliver in combination
therapy. Previous studies suggest that IL-24 selectively kills
melanoma cells via an IL-20 receptor-dependent pathway
that is independent of STAT3 [15]. In melanoma tumor
cells, IL-24 induces IFN-α, which leads to growth inhib-
ition and apoptosis, possibly involving FAS-FASL and
TRAIL interactions [16]. Since IFNs promote the activity
of STAT1 and SOCS1, but inhibits the activity of STAT3,
it is theoretically feasible that IFN-α and IL-24 may
augment their anti-tumor activities.
Interferon (IFN) inhibits the activity of tumor cells in
many organs and tissues and regulates activities of cyto-
kines which control cell function and replication. IFN
may mediate antitumor effects either indirectly by
modulating immunomodulatory and anti-angiogenic
responses, or directly by affecting proliferation or cellular
differentiation of tumor cells. Both the direct and indir-
ect effects of IFNs originate from the activation of the
JAK-STAT pathway and the induction of a subset of
genes, the IFN-stimulated genes (ISGs) [17]. Administra-
tion of high-dose IFN is associated with significant
toxicity that includes constitutional, neuropsychiatric,
hematologic, and hepatic effects [18]. When INF-α
expressed from an oncolytic adenovirus with the dl1101/
1107 mutation and with overexpressed E3 11.6 K adeno-
virus death protein was administered to nude mice,
efficacy against HCC tumors was improved and toxicity
was reduced [19]. This study suggests that co-administering
IFN-α with a replication-conditional oncolytic adenovirus
may both reduce the toxicity of IFN-α and increase its
efficacy, by locally high concentrations of IFN-α at the site
of the tumor, while systemic levels remained low. Recent
research suggests that interferon significantly improves the
effectiveness of chemotherapy, such as 5-fluorouracil and
S1 [20,21]. Also, IFN-α delays or reduces the recurrence of
liver cancer and improves the overall survival of patients
with HBV-related HCC [22]. Furthermore, low miR-26
expression in HCC was associated with greater sensitivity
to IFN therapy [23].
Oncolytic adenoviruses, which are gene therapy
vectors with intrinsic anti-tumor efficacy, have several
beneficial characteristics for their use against liver
cancer. First, oncolytic adenoviruses are engineered to
selectively replicate and lyze tumor cells but not normal
cells [24]. Because the lysed tumor cells release replica-
tion-conditional oncolytic adenoviruses that infect
surrounding tumor cells, they spread further into the
tumor nodules than such standard gene therapy vectors as
replication-defective adenoviruses [24]. Tumor-selective
replication of oncolytic adenoviruses is dependent on the
presence of tumor proteins that complement for the
engineered defect in the replication cycle of the oncolyticadenovirus. Fortunately, it is independent of p53 status.
Second, adenovirus type 5 specifically binds to hepatocytes
via coagulation factor X and heparin sulfate proteoglycans
[25]. Replication-competent oncolytic adenovirus SG600-
IL-24 has the telomerase reverse transcriptase promoter
(TERTp) and the hypoxia regulatory elements (HRE)
controlling the expression of adenoviral mutated E1a gene
and the E1b, respectively [26-28]. Mutation of the E1a
gene and its expression driven by the telomerase promoter
hinders its replication in normal cells but not in tumor
cells. Therefore SG600-IL-24 has enhanced effectiveness
and safety for cancer gene therapy. We have recently
shown that SG600-IL-24 inhibits growth and increases
apoptosis of several HCC cell lines in vitro [27,28].
The in vitro anti-tumor activity of oncolytic adenovirus
SG600-IL-24 was significantly greater than that of replica-
tion defective adenovirus IL-24 [27]. We hypothesized that
a three-prong strategy of INF-α, an oncolytic adenovirus,
and local expression of IL-24 would be more efficacious
than treatment with either IFN-α or an oncolytic adeno-
virus that expressed IL-24 locally. Here we compared the
efficacy of the IFN-α treatment, or intratumoral infection
oncolytic adenovirus that expressed IL-24, SG600-IL-24 or
both to a PBS control in a HCC xenograft in a nude mouse
model. To elucidate potential mechanisms, we also exam-
ined the effect of these three treatments and control on
the expression of the signaling molecules: STAT1, SOCS1,
and STAT3; and on the expression of proteins involved in
metastasis and angiogenesis: matrix metalloproteinases 2
(MMP-2), x-linked inhibitor-of-apoptosis protein (XIAP),
osteopontin (OPN), and vascular endothelial growth factor
(VEGF).
Results
SG600-IL-24 mediated ectopic IL-24 expression
SG600-IL-24 infection induced higher levels of IL-24
mRNA and protein expression in the normal liver cell
line L02, as well as in the HCC cell lines of differing
metastatic potential, HepG2, MHCC97L, and HCCLM3.
The HepG2 cell line was used to determine the expres-
sion of IL-24 protein after treatment with the PBS
control, IFN-α, and SG600-EGFP. In contrast, cells
treated with IFN-α, DMEM, or infected with the control
virus, SG600-EGFP, expressed very low or undetectable
concentrations of IL-24 mRNA or protein (Figure 1a, b).
Concentrations of IL-24 protein in supernatants of cells
treated with SG600-IL-24 significantly increased in a
time-dependent manner (Figure 1c).
Effect of SG600-IL-24 on cell viability
To assess whether the combined IFN-α and SG600-IL-24
treatment was more effective in suppressing cell viability,
the hepatocellular carcinoma cell lines HepG2, MHCC97L,
and HCCLM3, along with the normal liver cell line
Figure 1 Expression of adenovirus-mediated interleukin-24 mRNA. The hepatocellular carcinoma cell lines (HepG2, MHCC97L, HCCLM3) and
the human normal liver cell line L02 were treated with control media (Lane 1), treated with 1000 U/ml IFN-α (Lane 2), infected with SG600-EGFP
(Lane 3), or infected with SG600-IL-24 at MOI = 10 (Lane 4). a. Cells were harvested after 24 h, and RNA was isolated and amplified by RT-PCR as
described in “Materials and Methods”. Top line: RT-PCR with IL-24 primers. Bottom line: RT-PCR with β-Actin primers. b. Cells were collected 48 h
after infection, and protein lysates were isolated and analyzed by western blotting as described in “Materials and Methods”. The HepG2 cell line
was used to determine the expression of IL-24 protein after treatment with control, IFN-α, and SG600-EGFP. Top line: IL-24 Bottom line: β-Actin. c.
Using samples from the supernatant of treated cells, protein expression levels were determined 24 hours after IFN-α treatment, 24 hours after
SG600-EGFP treatment, and 24, 48, and 72 hours (as indicated) after SG600-IL-24 treatment.
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ted with both IFN-α and SG600-IL-24. Cell viability was
determined by MTT and compared to the media control.
These treatments did not affect the viability of the normalliver cell line L02 (Figure 2); In contrast, the viability of
HCC cell lines in the combined IFN-α and SG600-IL-24
treatment group as well as the SG600-IL-24 group were
significantly affected.
Figure 2 Cell viability of treated HCC cells and normal liver cells. HCC cells and normal liver cells were treated as indicated for 24, 48, 72, and
96 hours postinfection, and cell viability was assessed by the MTT assay. Results are presented as mean± SD (n = 5) of five independent
experiments and expressed as a percentage relative to the DMEM-treated control cells.
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but not in a normal liver cell line
Annexin-V and PI staining assays coupled with flow
cytometry quantified the effect of the various treatments
on inducting apoptosis in HCC cell lines (HepG2,
MHCC97L, and HCCLM3) and the normal liver cell L02
(Figure 3). The proportion of apoptotic HCC cells
increased significantly in cells treated with the combin-
ation of IFN-α and SG600-IL-24 infected compared with
cells treated with control, SG600-EGFP, and IFN-α cells
(p< 0.018). Both the HepG2 and L02 cells treated with
combined IFN-α and SG600-IL-24 had a significantly
higher percent of apoptosis than either treatment alone
(p< 0.01), although it was less than the sum of the
effects of both treatments.Figure 3 Combined therapy (IFN-α and SG600-IL-24) boosted apoptos
staining assays measured the effect of the indicated treatments on 3 HCC l
independent samples. Results are presented as mean± SD. The symbol * in
and †indicates a significant difference compared to the IFN-α group.IFN-α+ SG600-IL-24 inhibited HCCLM3 cell migration
The transwell assay assessed whether IFN-α or the
combination of IFN-α and SG600-IL-24 modulated
the process of HCCLM3 cell invasiveness. The
HCCLM3 cell line has a high potential for invasion
and metastasis compared with other hepatocellular
carcinoma cell lines. Migration through matrigel was
significantly decreased when HCCLM3 cells were
treated with IFN-α, SG600-IL-24, or the combination
of IFN-α and SG600-IL-24, compared with that the
control or SG600-EGFP groups (P< 0.01, Figure 4).
Treatment with the combination of both SG600-IL-24
and IFN-α significantly decreased migration compared
with either treatment alone (P-value = 0.004 and P-
value< 0.001).is in HCC lines but not in a normal liver cell line. Annexin-V and PI
ines and the normal liver cell line (LO2). Each group has five
dicates a significant difference compared to the SG600-IL-24 group,
Figure 4 Combined therapy (IFN-α and SG600-IL-24) inhibited HCCLM3 cell invasiveness. The number of HCCLM3 cells that invaded
the extracellular matrix and migrated through the polycarbonate membrane to the lower surface of the membrane was counted to
determine migration. The cells were treated as indicated by the column labels. The symbol * indicates a significant difference was
observed as compared to the SG600-IL-24 treatment group, and † indicates a significant difference was observed as compared to the
IFN-α group.
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in vitro
IFN-α signaling modulates expression of STAT1, SOCS1,
and STAT3. Since treating HCC cells for 24 or 48 hours
with IFN-α slightly increased the expression of STAT1
and had no obvious effects on SOCS1 expression, which
was similar to the patterns seen in the normal liver cell
line L02, we chose to use the IFN-α treatments for 24
and 48 hours as the background to see the effect of
combinations with the virus. We also evaluated the
expression of STAT1, SOCS1 and STAT3 in HepG2 and
L02 cells treated with SG600-EGFP or SG600-IL-24 forFigure 5 IFN-α increased STAT1 and SOCS1 mRNA levels, but decreas
and L02 cells were cultured with PBS, IFN-α, or both IFN-α and SG600-IL-24
and STAT3, along with β-actin, the internal control.24 and 48 h (Additional file 1: Figure S5). We showed
that combined therapy increased levels of SOCS1 mRNA
in HCC cell lines HepG2 and HCCLM3 in a time-
dependent manner, compared with either PBS or IFN-α
alone (Figure 5). Treatment with IFN-α resulted in
decreased STAT3 mRNA levels in the MHCC97L cell
line, which was further decreased when the IFN-α treat-
ment was combined with the SG600-IL-24 treatment.
While IFN-α did not affect SOCS1 or STAT3 mRNA
levels in the normal liver cell L02, IFN-α did increase
STAT1 mRNA levels (Figure 5). The data were obtained
from three independent experiments.ed STAT3 mRNA in HepG2, MHCC97L, and HCCLM3 cells. The HCC
for 48 hours. Then, RT-PCR assessed the mRNA levels of STAT1, SOCS1,
Wang et al. Molecular Cancer 2012, 11:31 Page 6 of 13
http://www.molecular-cancer.com/content/11/1/31MMP and VEGF expression
We analyzed the effect of IFN-α and the combined ther-
apy on expression of MMP-2, XIAP, OPN, and VEGF
proteins which are involved in cell invasiveness, metasta-
sis, and angiogenesis (Figure 6). We also included
HepG2 and L02 cells infected with SG600-EGFRP and
SG600-IL-24 for 24 or 48 h as a control (Additional file
2: Figure S6). IFN-α and the combined therapy decreased
protein levels of MMP-2, XIAP, OPN, and VEGF in the
HCC lines HepG2, MHCC97L, and HCCLM3 compared
with the expression levels of the control group. Both the
HepG2 and MHCC97L cell lines had greater decreases
in MMP-2, XIAP, and OPN when treated with the
combination of IFN-α and SG600-IL-24 than when trea-
ted with IFN-α alone. The HCCLM3 cell line had the
greatest reductions in the four proteins when it was
treated with the combined therapy. L02 cells treated
with IFN-α or with the combination of IFN-α and
SG600-IL-24 had minimal or no changes in protein
levels. The data were obtained from three independent
experiments.
SG600-IL-24 and IFN-α inhibited HCC tumor xenograft
growth and prolonged survival time of tumor-bearing mice
To evaluate the effect of these treatments on tumor
growth, we established HCCLM3 xenograft tumors in a
nude BALB/c mouse model. Four groups (n = 8 for each
group) of tumor-bearing mice were treated with PBS,
IFN-α, SG600-IL-24, or the combination of SG600-IL-24
and IFN-α. As expected, the group treated with PBS had
progressive tumor growth. Treatment with IFN-α or
SG600-IL-24 alone reduced or delayed tumor growthFigure 6 Expression of MMP-2, XIAP, OPN, and VEGF proteins in IFN-α
HepG2, MHCC97L, HCCLM3, and L02 lines were treated for 24 or 48 hours
relative concentrations of the MMP-2, XIAP, OPN, and VEGF proteins were cduring treatment. However, the combined therapy with
SG600-IL-24 and IFN-α resulted in substantial and long-
lasting suppression of tumor growth, which was signifi-
cantly greater than the other treatments (P< 0.01;
Figure 7a).
Survival times of mice in the IFN-α, SG600-IL-24, and
combination groups were significantly prolonged
compared with that of the PBS control group (P< 0.01;
Figure 7b). The median survival times were 35 days for
the control group, 59 days for the SG600-IL-24 group,
and 66 days for the IFN-α group. In comparison, the
median survival time of the combination group (SG600-
IL-24 + IFN-α) was 111 days and three of the eight
animals survived over 120 days with no evidence of
tumor (Figure 7b). Importantly, RT-PCR and immuno-
blotting demonstrated high levels of IL-24 mRNA and
protein in tumor tissue of treated mice even at 4 weeks
after infection with the oncolytic viruses (Additional file
3: for viral existence).
To begin to elucidate mechanisms mediating the
improved efficacy of the combined therapy group, we
assessed the expression of several proteins involved in
invasiveness and angiogenesis (MMP-2, XIAP, OPN, and
VEGF) in the tumor tissue of the treated groups. As
aforementioned, tumor tissue was only present in five of
the eight mice treated with the combined therapy. The
percent of tumor cells positive for MMP-2 expression
was significantly decreased in the INF-α group compared
with the controls, and the MMP-2 levels in the
combined therapy group were further significantly
reduced compared to the IFN-α, control, and IL-24
groups (Figure 8, Table 1). The percent of cells positivetreated or IFN-α combined with SG600-IL-24. Cells from the
with PBS, IFN-α, or the combination of IFN-α and SG600-IL-24. Then, the
ompared to β-actin on western blots
Figure 7 Antitumor activity of oncolytic adenovirus SG600-IL-24, IFN-α and their combination in HCCLM3 xenograft model. Tumor-
bearing mice were treated with PBS, IFN-α daily for 10 days, 2 x 108 PFU of SG600-IL-24 every 2 days for 10 days, or the combination of IFN-α and
SG600-IL-24 therapy for 10 days. A, Tumor was measured and volume was calculated, with the time shown from the start of treatment. Data
shows mean± SD (n = 8), though the error bar for the combined treatment group is too small to be clearly identified. B, Kaplan-Meier survival
curve. The symbol * indicates a significant difference was observed as compared to the SG600-IL-24 treatment group, and † indicates a significant
difference was observed as compared to the IFN-α group
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in the IL-24 group and the combined therapy group (Fig-
ure 8, Table 1). The percent positive cells for VEGF ex-
pression was significantly reduced by the three
treatments (IL-24, IFN-α, and the combined therapy)
(Figure 8, Table 1). These data indicated that thecombined therapy mediated its anti-tumor activity via
multiple pathways. Notably, the human IFN-α does not
cross-react with the mouse IFN receptor, and the human
IL-24 expressed by the virus does not cross-react with
the mouse IL-24 receptor. Both human and mouse IFN-
α can be detected by the ELISA kit.
Figure 8 Expression of MMP-2, OPN, VEGF, and XIAP in tumor tissue. Tumor tissues from five different mice from each group were stained
for MMP-2, OPN, VEGF, and XIAP expression by immunohistochemistry and visualized with a E80i microscope (Nikon Corporation, Japan) under
200x magnification
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To further elucidate the role of IFN-α, we assessed the
serum concentrations of IFN-α in the treated groups
compared to that of the control group. Blood samples
were collected from the four groups of mice after treat-
ment for a week followed by serum separation and
stored in −20°C. Serum concentrations of IFN-α were
57 ± 23 pg/ml in the control group, 280 ± 35 pg/ml in the
IFN-α group, 46 ± 22 pg/ml in the SG600-IL-24 group,
and 292 ± 52 pg/ml in the combined therapy group.
Discussion
Liver cancer gene therapy is a major research focus
because the 5-year survival for liver cancer patients is
10%, despite considerable advances in multimodality
treatment that include surgery, radiotherapy, andTable 1 Statistical analysis of immunohistochemistry on treat
Control(n = 5 mice) IL-24(n = 5 mice) IFN
MMP 74.0 ± 8.5 66.2 ± 10.2 48
OPN 68.0 ± 12.8 0.6 ± 0.9* 9.2
VEGF 17.8 ± 4.7 1.6 ± 1.1* 1.4
XIAP 90.8 ± 3.6 0.8 ± 0.4* 79
* significant difference compared to the control group,
† significant difference compared to the IL-24 group.
{ significant difference compared to the IFN-α group.chemotherapy [1]. Oncolytic adenoviruses have an
intrinsic specificity for liver cancer cells [25]. Recent
advances in vector development have improved tumor
specificity of its replication [26], in agreement with our
data in HCC lines. Infection with SG600-IL-24 displayed
CMV-driven IL-24 production in both normal cells L02
and in the 3 HCC cell lines. In contrast, viral induced
lysis was detectable only in the 3 HCC cell lines. Our
observed secretion of IL-24 can also contribute to the
potent “bystander” antitumor activity [29] and may target
micrometastases [14].
Comparable IL-24-induced anti-tumor activity in vitro
was observed in the three HCC cell lines which differed
by their metastatic potential; these data further
supported the findings that tumors which are sensitive to
mitochondrial dysfunction and apoptosis induced byed tumor tissues
-α(n = 5 mice) IL-24 and IFN-α(n = 5 mice) P-value
.0 ± 10.3* 2.0 ± 1.9*†{ <0.001
± 3.7*† 0.6 ± 0.5*{ <0.001
± 1.5* 0.8 ± 1.1* <0.001
.0 ± 7.0† 0.6 ± 0.5*{ <0.001
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including p53, p16/INK4a, and Rb [4,30,31]. The cell line
HepG2 expresses wild type p53 but has a mutant Rb,
while the cell lines MHCC97L and HCCLM3 have
mutant p53 [32-35]. The significantly improved median
survival time, the 37% long term survivors, and the
significantly lower tumor volume in the combined
therapy (SG600-IL-24 and IFN-α) compared to those of
the single modality groups and controls suggests that
these modalities complement their anti-tumor activities.
We have just begun to elucidate mechanisms for this
interaction. It is important to note that the lack of IFN-α
toxicity in mice as a result of systemic administration
in this study could be due to species specificity of the
IFN-α receptor. This needs to be kept in mind while
extrapolating these data to humans.
The SG600-IL-24 virus selectively lyses melanoma cells
via an IL-20 receptor-dependent mechanism which is
independent of the STAT3 pathway [15]. It is feasible
that the SG600-IL-24 virus mediates its anti-tumor activ-
ity via STAT3 inhibition. While IFN-α can promote the
activity of STAT1 and SOCS1 definitely, IFN-α inhibits
the activity of STAT3, in accordance with these studies.
Activating STAT3 is necessary for the VEGF receptor
signaling pathway in endothelial cells [36,37]. Blocking
the expression of STAT3 inhibits the migration and
lumen formation of endothelial cells [37]. Persistent
STAT3 activity promotes in vivo angiogenesis, in part by
inducing VEGF, a potent inducer of angiogenesis [38,39].
Persistent activated STAT3 also stimulates invasiveness
and metastasis by inducing MMP-2 in vitro and in vivo
[39]. Thus, inhibition of aberrant STAT3 suppresses
VEGF expression and angiogenesis [38,39]. XIAP is the
most potent caspase inhibitor [40], and it is increased in
HCC [41]. High XIAP are associated with reduced
survival [42]. High intracellular OPN regulates cell sur-
vival and is essential both for IFN-α production by plas-
macytoid dendritic cells [43] and for the migration of
metastatic tumor cells [44]. Our results suggest that IFN-α
or combined therapy with SG600-IL-24 inhibited the levels
of STAT3 in HCC cell lines, and reduced levels of down-
stream proteins including MMP-2, XIAP, OPN, and VEGF.
This led to increased rates of apoptosis in hepatoma cells
and significantly decreased metastatic potential.
Although increasing chemotherapeutic drug concen-
trations causes greater tumor cell death, harmful effects
are also seen in normal cells, which may lead to failure
of therapy failure because the treatment can be intoler-
able for patients. Therefore, approaches are critically
needed that maximize the chemotherapeutic effect and
allow both the drug dosage and the length of treatment
to be reduced. Previous studies suggest that IL-24 and
radiotherapy synergistically destroy tumors, inhibit
tumor growth, and reduce intratumor angiogenesis[45,46]. We hypothesized that IFN-α combined with the
oncolytic adenovirus SG600-IL-24 would provide greater
efficacy against HCC. Our results demonstrated that the
combined therapy had a significantly smaller mean
tumor volume and increased survival time, with three of
eight mice being long-term survivors. Thus, the dosage
can be decreased and the corresponding toxicity
reduced. The viruses continue to exist in the tumors, as
the oncolytic adenovirus exists at both the mRNA and
protein levels four weeks after infection [47].
Notably, we determined the specific activity of the
serum IFN-α by ELISA, where standards are prepared in
pg/ml. Commercialized IFN-α preparations are sold with
activity described based on a viral resistance assay that
uses bovine kidney MDBK cells to define IU/mg. Our
study did not test the bioactivity of the serum IFN-α, so
our study is limited by our inability to correlate the levels
detected (expressed in pg/ml) to the doses administered
(expressed in IU/mg). Additionally, the effects observed
when we combined IFN-α with SG600-IL-24 in vitro
differed from those observed in vivo. The anti-tumor ac-
tivity of IL-24 was previously shown to be mediated by
an IL-20 receptor-dependent but STAT3-independent
mechanism [15]. Furthermore, INF-α was shown to acti-
vate of STAT1 and SOCS1 while inhibiting STAT3 in
order to promote angiogenesis [38,39]. Our mRNA and
protein expression measurements (Figure 5 and 6) were
therefore designed based on IFN-α signaling and did not
include an IL-24 group. Our goal was to understand if
combining IFN-α with IL-24 could enhance anti-tumor
activity via inhibition of STAT3 to promote anti-angio-
genic effects.
In summary, this study demonstrated that combining
SG600-IL-24 and IFN-α resulted in significantly longer
mean survival time, along with lower levels of the
proteins VEGF, OPN, STAT3, and XIAP. These findings
suggest that targeting gene-virotherapy combined with
IFN-α can provide an efficient strategy in HCC cancer
treatment and warrants further development.
Materials and methods
Cell lines, culture conditions, reagents and mice
The HCC cell lines (HepG2, MHCC97L, and HCCLM3)
and the normal human liver cell line L02 were purchased
from the Institute of HCC of Fudan University. Cell lines
were cultured in high glucose DMEM (HyClone, USA)
supplemented with 10% FBS (Gibco, USA). L02 cells
were cultured in RPMI-1640 (HyClone, USA) supple-
mented with 10% FBS. All cell lines were cultured at 37°
C in a 5% CO2 humidified incubator.
Virus construction and production
The oncolytic adenovirus which expressed enhanced
green fluorescent protein, SG600-EGFP was constructed
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[28]. The SG600 adenovirus is regulated by the hTERT
promoter and is replication competent. The adenoviral
E1a gene is driven by the hTERT promoter sequence.
The SG600 adenovirus can selectively replicate in a
broad array of human cancer cells with positive telomer-
ase activity, but not in normal cells. Both IL-24 and
EGFP were driven by the CMV promoter. Genomes were
analyzed to confirm the recombinant structure. Due to
nomenclature change, SG600.mda-7 was renamed
SG600-IL-24. The virus was plaque purified, amplified in
HEK293 cells, and stored in aliquots at −80°C. Viral
titers were determined by TCID50 assay in HEK293
cells. The titers were 2.25 × 1010 plaque-forming units
(PFU)/ml for SG600-IL-24, and 2.79 × 1010 PFU/ml for
SG600-EGFP.
Viral infection and IFN-α treatment
Six-well plates for each cell line were divided into 4
groups: control, IFN-α, SG600-EGFP, and SG600-IL-24
groups. The control group was incubated with serum-
free DMEM for 24 h. Cells in the SG600-EGFP and
SG600-IL-24 groups were infected with their respective
viruses at a multiplicity of infection (MOI) of 10. The
IFN-α group was incubated with 1000 U/ml of IFN-α
(Sigma, St. Louis, MO, USA) for the same time period.
RT-PCR
To quantitate IL-24 RNA, cells were infected with
SG600-IL-24 (MOI = 10), incubated 24 h, and harvested.
Total RNA was extracted and RT-PCR was performed as
previously described [28,48]. Primer sequences of IL-24
mRNA (sense: 5'-GGG CTG TGA AAG ACA CTA T-3';
antisense: 5'-GCA TCC AGG TCA GAA GAA-3') ampli-
fied a 381 bp fragment. Primer sequences of β-Actin
(sense: 5'-CCT TCC TGG GCA ATG GAG TCC T-3';
antisense, 5'-GGA ACA ATG ATC TTG ATC TT-3')
amplified a 201 bp fragment. PCR conditions (RT-PCR
kit (TAKARA, JPN)) were denaturation at 94°C for
5 min; 30 cycles of denaturation at 94°C for 30 s, anneal-
ing at 56°C for 30 s, and extension at 72°C for 45 s; and
extension at 72°C for 10 min to ensure full extension of
the product. The amplified products were visualized by
electrophoresis on a 1% agarose gel. To quantitate apop-
totic genes, cells were treated with PBS, IFN-α (1000 U/
ml), or IFN-α combined with SG600-IL-24 (MOI = 10).
We harvested the cells and RNA in the PBS group after
24 h, and the cells treated with IFN-α group or the com-
bined therapy at 24 and 48 h. Primer sequences for
STAT1 (sense: 5'- TTCTGGCCTTGGATTGAC-3';
antisense, 5'-TCTCAGCAGCCATGACTT-3') ampli-
fied a 313 bp fragment; SOCS1 primers (sense, 5'- 5’-
AGACCCCTTCTCACCTCTTG-3'; antisense, 5'-
CTGCACAGCAGAAAATAAAGC -3') amplified a 202 bpfragment; and STAT3 primers (sense, 5'- CGTCCAGTT-
CACTACTAAAGTCAGG -3', antisense, 5'- CTCAGTCA-
CAATCAGGGAAGCA -3') amplified a 277 bp fragment.
ELISA
Cell culture supernatants were collected at 24, 48, and
72 h and stored at −20°C. Concentrations of IL-24 were
determined by IL-24 ELISA (R&D Systems, Minneapolis,
MN, USA) using a standard curve. Absorbance was read
at 450 nm. Serum concentrations of IFN-α in the tumor-
bearing mice were measured using an ELISA kit (R&D
Systems, Minneapolis, MN, USA).
MTT assay to determine cell growth
A total of 103 cells were seeded into 96-well tissue cul-
ture plates, and treated with PBS, 1000 U/ml IFN-α,10
MOI of SG600-EGFP, 10 MOI of SG600-IL-24, or both
1000 U/ml IFN-α and 10 MOI of SG600-IL-24. After the
indicated times, media was removed, and fresh medium
with 0.5 mg/ml MTT (Sigma, St. Louis, MO, USA) was
added to each well. After cells were incubated at 37°C
for 4 h, supernatant was removed, 150 μl dimethylsulfox-
ide was added to each well, and the cells were incubated
for another 10 min at 37°C with gentle shaking. Absorb-
ance was read on a Bio-Rad microplate reader at 595 nm
[24].
Western blot analysis
Cell lines were cultured in six-well plates, treated with
the different treatments, and collected at the indicated
times. Next, the cells were suspended in RIPA lysis
buffer that contained protease inhibitors and then quan-
titated by the BCA method. To quantitate IL-24, 25 μg
protein samples were separated by 15% SDS-PAGE and
then transferred to polyvinylidene fluoride (PVDF)
membranes. The PVDF membranes were probed with
polyclonal antibodies either to mda-7/IL-24 (Abcam,
UK) or to β-actin, then corresponding fluorescent
secondary antibody was added, and then the fluorescence
signal was detected with the infrared imaging systems.
To quantitate apoptotic genes, 50 μg protein samples
were separated on an 8-15% SDS-PAGE gel and trans-
ferred to PVDF membranes. The PVDF membranes were
probed with polyclonal or monoclonal antibodies to
STAT1, SOCS1, STAT3, MMP-2, XIAP, OPN, VEGF, and
β-actin (Thermo Scientific, Lab Vision, CA, USA). The
blots were evaluated with enhanced chemiluminescence
(ECL), and β-actin was detected on the same membrane
and used as a loading control.
Hoechst33258 staining
Cells were infected, incubated for 48 h, washed twice
with PBS, and fixed in 1 ml of 4% paraformaldehyde for
10 min at 4°C. After two washes with PBS, cells were
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15 min in the dark at room temperature, and then 1000
stained cells were examined for nuclear fragmentation
with a TE2000-U fluorescence microscope (Nikon,
Japan). Apoptotic cells were identified by the nuclear
chromatin condensing and fragmenting.
Fluorescence-activated cell sorter (FACS) analysis
Cells were harvested 48 h after treatment, trypsinized,
and washed twice with complete media. A total of 106
cells were resuspended in 500 μl binding buffer and
stained with 5 μl fluorescein isothiocyanate (FITC)-la-
beled Annexin-V (Annexin-V/PI kit, Sigma). A total of
0.25 μg propidium iodide (PI) was added to the samples
after staining with Annexin-V, and then the samples
were incubated in the dark for 30 min. Flow cytometry
(BD, FACSCalibur, USA) was performed immediately
after staining.
Transwell assay
Cell migration analysis was performed by using a Trans-
well (Corning, NY). The transwell chamber containing
an 8-μm pore size polycarbonate membrane filter coated
with a matrigel (16.5μL/membrane filter, BD Bioscience,
Bedford, MA) was inserted in a 24-well culture plate.
Cells were infected and harvested after 48 h. A total of
100μL of 2 × 105 cells were placed in the upper transwell
chamber in serum-free DMEM high glucose culture
medium. A total of 600 μL of high glucose DMEM
media containing 10% fetal bovine serum was added into
the lower transwell chamber. After reculturing with 5%
CO2 at 37°C for 20 h, the transwell chambers were
inverted and stained with Giemsa for 15 min. Five
fields were randomly selected and the number of trans-
membrane cells in those fields was counted.
Animal studies
Male BALB/c nude mice at 4 to 6 weeks of age were
obtained from Liver Cancer Institute of Zhongshan
Hospital, Fudan University (Shanghai, China) and main-
tained in pathogen-free conditions in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals. A total of 2 × 106 HCCLM3 cells
were injected subcutaneously (s.c.) into the right flanks of
mice. When tumors reached 100–150 mm3, mice were
randomly divided into four treatment groups (n= 8 each):
control (saline injection), IFN-α alone (1.5 × 104 IU/g of
human IFN-α, intraperitoneal (i.p.) injection, once per day
for 10 days), SG600-IL-24 alone (2× 108 PFU, 5 intratumor
(i.t.) injections on 2 day intervals for 10 days), or combin-
ation (SG600-IL-24 with 2× 108 PFU and also IFN-α with
1.5× 104 IU/g, both over 10 days). Tumor length and
width was measured twice weekly, and tumor volume was
calculated as follows: Tumor volume= length x width2/2.Survival time was also monitored with a survival of more
than 120 days considered long-term survival.
Immunohistochemical analysis of tumors
Tumors of the five mice from each treatment group were
harvested on day 30 for hematoxylin/eosin staining and
examined for tumor cell differentiation. We performed
immunohistochemical staining to detect expression of
MMP-2, X-IAP, osteopontin, and VEGF. Formalin-fixed
tissue sections that were 5 μm wide were mounted on
microscope slides, dried overnight at 60°C, dewaxed in
xylene, and rehydrated with distilled water. Endogenous
peroxidase was quenched by treating the sections with
1% H2O2 in methanol for 10 min. Sections were incu-
bated overnight at 4°C with 1:500 dilutions of rabbit
polyclonal antibody to MMP-2, X-IAP, osteopontin, and
VEGF (Thermo Scientific, Lab Vision, CA, USA), washed
with PBS three times, and then incubated with the
appropriate secondary antibody (Santa Cruz Biotech).
After washing in PBS three times, the sections were
treated with DAB substrate and hematoxylin as a
counterstaining reagent. To determine the percentage of
positive cells, at least 1000 cells/slide were counted and
scored by an E80i microscope (Nikon, Japan) under 200×
magnification.
Statistical analysis
All analyses were performed with SPSS14.0 software.
The experiments were performed at least three times.
Results are expressed as mean ± standard deviation (SD).
Statistical comparisons were made using analysis of
variance (ANOVA). Values of p< 0.05 were considered
statistically significant.
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